<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) represents a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of potentially malignant <z:e sem="disease" ids="C0005940" disease_type="Disease or Syndrome" abbrv="">diseases of bone</z:e>-marrow stem cells </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is an inevitable outcome for many patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> has been reported to result in comparably higher response rates and improved survival than other treatment strategies </plain></SENT>
<SENT sid="3" pm="."><plain>In this retrospective study, we report the results on 25 'real life' patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> between 2005 and 2009 </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients fulfilled the World Health Organization criteria for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>No eligibility criteria other than diagnosis were considered </plain></SENT>
<SENT sid="6" pm="."><plain>Complete response (CR) rate was observed in three of the 25 'real life' patients (12%) with a median duration of CR of 5 months (4-6 months) </plain></SENT>
<SENT sid="7" pm="."><plain>Seven patients (28%) had mono- or bi-lineage haematologic improvement and 15 patients (60%) showed neither morphologic nor haematologic response </plain></SENT>
<SENT sid="8" pm="."><plain>Among 17 non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, the median time from <z:hpo ids='HP_0003674'>onset</z:hpo> of Aza-C treatment to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation was 10 months (4-15 months) </plain></SENT>
<SENT sid="9" pm="."><plain>Overall <z:hpo ids='HP_0011420'>death</z:hpo> rate was 72% </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the eight <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients died </plain></SENT>
<SENT sid="11" pm="."><plain>The <z:hpo ids='HP_0011420'>death</z:hpo> rate under Aza-C among non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients was 59% </plain></SENT>
<SENT sid="12" pm="."><plain>Unlike the results of the clinical trials, our data show that Aza-C has a limited activity in 'real-life' patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>It is obvious that Aza-C can induce complete or partial responses in a considerable number of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients but responses are usually not durable as we observed in our patients </plain></SENT>
</text></document>